Clinical Research Papers:

Isolated locoregional recurrence patterns of breast cancer after mastectomy and adjuvant systemic therapies in the contemporary era

Jinli Ma _, Rui Jiang, Lihua Fan, Xin Mei, Zhaozhi Yang, Xiaoli Yu, Xiaomao Guo, Zhen Zhang and Zhimin Shao

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:36860-36869. https://doi.org/10.18632/oncotarget.5365

Metrics: PDF 2013 views  |   HTML 1944 views  |   ?  


Jinli Ma1,4,*, Rui Jiang1,4,*, Lihua Fan2, Xin Mei1,4, Zhaozhi Yang1,4, Xiaoli Yu1,4, Xiaomao Guo1,4, Zhen Zhang1,4, Zhimin Shao3,4

1Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

2Department of Radiation Oncology, Jingjiang People's Hospital, Jingjiang, China

3Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

4Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

*These authors have contributed equally to this work

Correspondence to:

Jinli Ma, e-mail: [email protected]

Keywords: breast cancer, mastectomy, isolated locoregional recurrence, recurrence pattern, biologic subtype

Received: July 26, 2015     Accepted: September 11, 2015     Published: September 23, 2015


Purpose: To evaluate the recurrence patterns in a series of patients who presented with isolated locoregional recurrences (ILRRs) after mastectomy and adjuvant systemic therapies in the contemporary era.

Methods: A total of 235 patients who developed ILRRs between 2005 and 2013 were classified into subgroups based on nodal status, hormone receptor status, and biologic subtype. The annual frequency of recurrences, association between biologic subtype and interval to recurrence (ITR), and anatomical distribution were evaluated.

Results: For the entire group, recurrence peaked within the first 3 years after mastectomy, and then decreased significantly with time. Node-positive patients were observed to recur early, and a greater proportion recurred within 5 years (86.7% vs. 72.8%, χ2 = 6.83, P = 0.008) than did node-negative subgroup. Overall, the median ITR was 33.2 (range, 4.5 – 236) months. Biologic subtype specific median ITR were 43.3 (7.9 – 236.0) months for luminal A, 42.2 (6.1 – 143.3) months for luminal B, 23.8 (6.9 – 47.3) months for luminal HER2, 18.2 (6.6 – 117.5) months for HER2, and 21.8 (4.5 – 138.2) months for TNBC, and their difference was statistically significant (χ2 = 7.4, P = 0.001). Among all ILRRs, 51.5% (n = 121) were isolated to regional nodes.

Conclusions: We demonstrates that the time course is consistent with previous description, biologic subtype is associated with ITR, and regional nodes is the most common place for recurrences in this series of patients who developed ILRRs following mastectomy and contemporary adjuvant systemic therapies but without PMRT.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5365